The premenopausal circulating lipid profile may be linked to the hormonal profile and ovarian lipid metabolism.
(HDL) cholesterol levels (1) (2) (3) (4) (5) (6) (7) . In the largest study to date, circulating lipids were determined in 259 normally menstruating women at up to 8 times during the menstrual cycle (8) . There was a statistically significant decrease in total and LDL cholesterol levels during the luteal phase as compared with the follicular phase, and a statistically significant increase in HDL cholesterol level near the time of ovulation (8) . These changes in lipoprotein levels correlate with periods of elevated estradiol concentrations and are consistent with the known effects of hormone replacement therapy on lipoproteins in postmenopausal women (9) (10) (11) (12) (13) . Collectively, these data indicate that endogenous estradiol controls cyclic variations in lipoproteins in premenopausal women.
A possible novel factor contributing to the premenopausal lipid profile is ovarian lipid metabolism. We have reported that the primate corpus luteum (CL) expresses several genes whose protein products increase HDL formation, some of which are selectively expressed in a limited number of tissues and include the apolipoproteins A1 and E (14) . Genes associated with LDL and very low-density lipoprotein synthesis (e.g., apolipoprotein B, cholesterol ester transfer protein) are not expressed in the primate CL (15, 16) . Also, the primate CL is a highly steroidogenic gland that has been estimated to produce 40 mg of progesterone per day in humans (17) , with uptake of LDL being the primary cholesterol source supporting steroidogenesis (18) . Because estradiol and progesterone may directly impact blood lipid concentrations, assessing the independent role of ovarian lipid metabolism is difficult. Therefore, the primary objective of this study was to assess whether ovarian metabolism, independent of the systemic effects of ovarian-derived estradiol and progesterone, contributes to the premenopausal lipid profile. A second objective was to evaluate the acute effects on circulating lipids of a commonly used monophasic combined hormonal oral contraceptive (OC) relative to the normal menstrual cycle.
Materials and Methods

Subject recruitment and enrollment
Participants were recruited at two academic hospitals during this study. The institutional review board of each institution reviewed and approved the study, and all participants provided informed written consent. Participants were recruited at Oregon Health & Science University (OHSU) from March 2012 until June 2012. Recruitment was then continued at the University of Arizona from March 2014 until June 2015. Healthy, premenopausal women, aged 21 to 40 years, with self-reported normal menstrual cycles (defined as 24 to 35 days long for three previous cycles) and a body mass index of at least 18 kg/m 2 but ,30 kg/m 2 were recruited. Key exclusions included depot medroxyprogesterone acetate in the last year, other hormonal contraceptives within the previous 2 months, current or recent pregnancy (within the previous 6 months), trying to conceive, current or recent breastfeeding (within 2 months), smoking or a history of substance abuse, and medical contraindications to study interventions. Participants were asked to maintain their normal dietary and lifestyle habits throughout study participation.
Study design
A crossover design was used. Interventions and specimen collection were similar at both institutions with specific differences noted later. Up to 20 blood samples were collected from each participant during 4 unique physiologic states: natural menstrual cycle (n = 7 samples), an OC cycle (n = 3 samples), menopause (n = 3 samples), and hormone replacement (artificial cycle) to mimic a natural menstrual cycle [n = 7 samples; Fig.  1(A) ]. After recruitment and enrollment, participants were screened to ensure they were currently ovulatory [OHSU participants: serum progesterone .3 ng/mL during days 18 to 25 of cycle; University of Arizona participants: urinary detection of luteinizing hormone (LH) surge]. During the natural cycle, all participants used a home fertility monitor (Clearblue; Procter & Gamble, Cincinnati, OH) that tests for a urinary metabolite of estradiol (estrone-3-glucuronide) and LH, to aid in timing of specimen collection. The fertility monitor has three possible results: (1) low fertility (low estradiol), (2) high fertility (estradiol increasing), and (3) peak fertility (LH surge).
Participants returned to the clinic for blood collection at the following seven time points during their natural cycle: (1) midfollicular (days 7 to 9 after first day of menses); (2) late follicular (1 to 3 days after initial high fertility result); (3) ovulation (0 to 2 days post-LH surge); (4) early luteal (4 to 6 days or 3 to 5 days post-LH surge, OHSU or University of Arizona, respectively); (5) midluteal (7 to 9 days post LH-surge); (6) late luteal (12 to 14 days or 10 to 12 days post LH-surge, OHSU or University of Arizona, respectively); and (7) menses (days 1 to 3 after first day of menses). Participants were then provided a commonly prescribed monophasic combined hormonal OC (Portia; Barr Laboratories Inc., Pomona, NY; 30 mg of ethinyl estradiol and 150 mg of levonorgestrel per active pill) for 3 weeks, with blood samples collected at the end of each week (OC cycle). After the OC cycle, participants received the gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate (Eligard; Sanofi-Aventis, Bridgewater, NJ) in a 22.5-mg depot subcutaneous injection. After a 4-week rest period to allow the GnRH agonist to take effect, 3 blood samples were collected 1 week apart (menopause).
Finally, participants were provided with transdermal estradiol patches (Vivelle-Dot; Novartis Pharmaceuticals, East Hanover, NJ) and vaginal micronized progesterone suppositories (OHSU participants: FIRST-Progesterone VGS; CutisPharma, Woburn, MA; University of Arizona participants: Endometrin; Ferring Pharmaceuticals, Parsippany, NJ), and were given an application schedule designed to mimic normal levels of these hormones over 28 days (artificial cycle). Seven blood samples were collected during the artificial cycle at time points analogous to the natural cycle in terms of expected circulating estradiol and progesterone concentrations. The artificial-cycle hormone replacement schedule and blood collection windows at each institution are detailed in Supplemental Tables 1 and 2 .
Biochemical analyses
Participants fasted overnight before blood draws. Blood was kept at room temperature for 30 to 60 minutes to allow formation of a clot, then it was centrifuged to harvest serum. Aliquots of serum were stored at 280°C until analyzed. Concentrations of estradiol and progesterone in serum were determined by the Endocrine Technologies Support Core at the Oregon National Primate Research Center, OHSU. Estradiol and progesterone were analyzed using a Roche Cobas e411 automated clinical platform (Roche Diagnostics, Indianapolis, IN). The assay-sensitivity ranges of the estradiol and progesterone assays were 5 to 4300 pg/mL and 0.030 to 60 ng/mL, respectively. Intra-and interassay coefficient of variations for the Roche assays are consistently ,7%.
Lipid profiles were obtained using an in-house fluorometric enzyme assay for cholesterol that was based on a published method (19) and a commercial triglyceride colorimetric assay (Pointe Scientific, Canton, MI). Briefly, serum was mixed in a 1:1 ratio with 15% polyethylene glycol 6000 to precipitate non-HDL lipoproteins. After centrifugation at 2000g for 10 minutes at room temperature, cholesterol concentrations were determined in the supernatant (HDL fraction) and whole serum. Triglyceride concentrations were quantified in whole serum, and LDL cholesterol concentrations were calculated using the Friedewald equation (20) . Quality controls consisting of 2 samples of human sera with known concentrations of each lipid (Pointe Scientific) were simultaneously quantified in each assay to validate accuracy and calculate precision (Supplemental Table 3 ). Each lipid measurement for each subject was quantified within the same assay, and the average interassay coefficient of variation for all lipid measurements was within the range of 4% to 9%.
Statistical analyses
Statistical analyses were performed using Stata version 14 (StataCorp, College Station, TX). The total to HDL cholesterol ratio (TC:H ratio) and individual lipid levels were primary outcomes. Mixed-effects regression analysis was used to account for repeated measures with variables as fixed effects and subject identification as the random effect. The percent changes attributable to each variable discussed in Results were calculated by dividing the mean b coefficient for the respective variable into the baseline. All differences were considered significant at P , 0.05, with P values of 0.05 to 0.10 considered trends.
Regression model 1
Specimens from the natural cycle, menopause, and the artificial cycle were used in this comparison. Serum concentrations of estradiol and progesterone, and active ovary (a binary variable coded 1 for natural-cycle specimens when the ovary is active and 0 for menopause and artificial-cycle specimens when the ovary is inactive) were fixed effects. Statistical analysis used actual estradiol and progesterone concentrations in serum, which helped account for the subtle differences in hormone replacement doses and timing of specimen collection at the two sites. The b coefficients for estradiol and progesterone represent the change attributed to each unit of hormone [i.e., for each measure of estradiol (pg/mL) and progesterone (ng/mL)]. Therefore, for presentation purposes, the coefficients were expressed in physiologically relevant levels by multiplying the estradiol coefficients by 100 (per 100 pg/mL) and progesterone coefficients by 10 (per 10 ng/mL).
A subgroup analysis was performed with the same regression procedure, using only follicular phase or luteal phase data. The follicular-phase subgroup analysis consisted of the midfollicular, late-follicular, and ovulation specimens from the natural cycle and the analogous samples from the artificial cycle, as well as the menopause specimens. Although the collection window for the ovulation specimen extended into the first 1 to 2 days of the luteal phase, to test for an ovarian effect, it was assigned to the follicular-phase subgroup because it represented the ovulating follicle. The luteal-phase subgroup analysis also used the menopause specimens, along with the early luteal, midluteal, late luteal, and menses time points from the natural menstrual cycle and the analogous samples from the artificial cycle. Although the menses specimens were from the early follicular phase of the successive cycle, to evaluate the ovarian effect, they were assigned to the luteal phase because, during this time point, follicular development is minimal and the CL from the previous cycle is still present and retains some functional capacity (18) .
Regression model 2
Specimens from the normal menstrual cycle and the OC cycle were used in this comparison. Concentrations of estradiol and progesterone were not used in this regression model, because they cannot be directly compared with the synthetic estrogen and progestin in the OC.
Results
Of the six participants recruited at OHSU, five were enrolled (one was excluded for medical contraindications), and four completed the protocol (one was lost to follow-up for unknown reasons). Of the 12 participants recruited at the University of Arizona, 10 enrolled in the study (two were excluded for body mass index .30 kg/m 2 ); four of these completed the entire protocol and one completed through the OC cycle before withdrawing (because of relocation). Of the five enrolled participants who did not complete the protocol in Arizona, two did not meet screening criteria (one for an abnormal menstrual cycle, and one became pregnant) and three were lost to follow-up for unknown reasons. Characteristics of the eight participants who completed the entire protocol are listed in Supplemental Table 4 . Four participants classified themselves as white, one as African American, one as Asian, two as multiracial, and one as having Hispanic/Latina ethnicity. Data from the subject who completed the study through OC cycle 2 before withdrawing were included only in regression model 2.
Serum concentrations of estradiol and progesterone are shown in Fig. 1(B) . As expected, serum concentrations of both hormones were dramatically suppressed during the OC cycle and simulated menopause. Administration of transdermal estradiol and vaginal progesterone according to the study protocol resulted in circulating steroid concentrations that were similar in pattern to those observed during the natural menstrual cycle [ Fig.  1(B) ]. Compared with the natural cycle, actual estradiol concentrations during the artificial cycle tended to be lower during the follicular phase (P = 0.053), but were not significantly different during the luteal phase (P = 0.146; Supplemental Table 5 ). Actual concentrations of progesterone were not significantly different between the artificial and natural cycles (Supplemental Table 5 ).
Results of statistical analysis of the association of each variable (i.e., estradiol, progesterone, ovarian effects) with the outcomes of regression model 1 are listed in Table 1 . For visual comparison, all outcomes at each time point throughout the study are shown in Fig. 2 . When analyzing across the entire menstrual cycle, the TC:H ratio was significantly reduced in association with an ovarian effect and independent of estradiol or progesterone (~4.2%; P = 0.003). There was also an ovarian effect associated with significantly reduced total cholesterol (~5.1%; P = 0.029) and LDL cholesterol (~7.3%; P = 0.009) levels independent of either estradiol or progesterone. Estradiol level was significantly associated with increased levels of total cholesterol (~3.6% per 100 pg/mL; P = 0.019) and HDL cholesterol (~5.5% per 100 pg/mL; P , 0.001), whereas progesterone level was significantly associated with reduced HDL cholesterol (~4.2% per 10 ng/mL; P = 0.044).
Specimens from the follicular and luteal phases (and the corresponding samples from the artificial cycle) were analyzed separately to assess whether the ovarian effects were attributable to the follicle and/or CL. In the follicular-phase subgroup (Table 2) , a statistically significant association of ovarian activity with a reduced TC:H ratio was observed (~6.7%; P = 0.001), which was accompanied by a statistically significant ovarian effect on increased HDL cholesterol level (~6.9%; P = 0.049). Estradiol itself was associated with increased HDL cholesterol levels during the follicular phase (~3.8% per 100 pg/mL; P = 0.032). In the luteal-phase subgroup (Table 3) , there was no ovarian effect on the TC:H ratio. The CL itself (ovarian effect) was associated with significantly reduced levels of total cholesterol (~10.4%; P , 0.001), HDL cholesterol (~8.1%; P = 0.005), and LDL cholesterol (12.1%; P , 0.001). There were no statistically significant associations between estradiol or progesterone and any outcomes during the luteal phase. Alternative statistical modeling of the luteal-phase subgroup was used to test the sensitivity of the primary analysis. Exclusion of the menses specimens from the luteal-phase subgroup regression model did not alter the identification of any statistically significant associations. In an alternative method, a paired t test of the midluteal-phase specimens from the natural and artificial cycles revealed a significant decrease (P = 0.041) in LDL cholesterol levels during the natural cycle, whereas estradiol, progesterone, and other lipid concentrations were not significantly different.
The second regression model was to evaluate the acute effects of the OC cycle relative to the normal menstrual cycle. Results of statistical analysis of outcomes for regression model 2 are listed in Table 4 . The TC:H ratio (~7.5%; P = 0.002) and triglyceride level (~33.0%; P , 0.001) were significantly increased with OC use, and HDL cholesterol level tended to fall (~6.4%; P = 0.051).
Discussion
The major objective of this study was to assess the individual contributions of estradiol, progesterone, and ovarian lipid metabolism to the circulating lipid profile. As previously described, the luteal phase has been reported to have reduced total and LDL cholesterol levels relative to the follicular phase (1, 2, 4-8). The lutealphase effect has been attributed to endogenous estradiol, because serum concentrations of estradiol are higher during the luteal phase than the follicular phase (with the exception of the midcycle estradiol surge in the late follicular phase), and orally (and transdermally, to a lesser extent) administered estrogens decrease total and LDL cholesterol concentrations in premenopausal and postmenopausal women (21) . In the luteal-phase subgroup analysis, neither estradiol nor progesterone was significantly associated with changes in any lipids. However, there was an ovarian effect associated with reduced total and LDL cholesterol levels when analyzed across the entire menstrual cycle, and an even greater reduction in total and LDL cholesterol levels was associated with ovarian actions in the luteal-phase subgroup analysis. The latter result is likely an effect of the CL, because it is the dominant ovarian structure during the luteal phase. This indicates that previous reports of reductions in total (2, 6, 8) and/or LDL cholesterol levels (1, 2, 4-6, 8) during the luteal phase may not have been due solely to estradiol but also to luteal consumption of cholesterol. It has been well established that the primate CL principally uses LDL-derived cholesterol to support its high levels of steroid production, and the CL maintains a considerable cholesterol reserve within lipid droplets that is necessary to support enhanced steroidogenesis in response to luteotropic stimuli such as human chorionic gonadotropin during early pregnancy (18) . Thus, the CL may deplete LDL cholesterol from the circulation to maintain steroidogenesis and its endogenous cholesterol reserves. Because the CL is the principal source of estradiol and progesterone during the luteal phase of the menstrual cycle but also may directly metabolize circulating lipids, this could at least partially explain some of the apparent discrepancies between the actual effects of exogenous hormone replacement on lipoprotein metabolism and the predicted effects based on cyclic correlations between endogenous hormones and lipoproteins (21) .
It was previously reported that circulating HDL cholesterol level increases near the time of the midcycle estradiol surge (3, 5, 7, 8 ). In the current study, the estradiol level was associated with significantly increased total and HDL cholesterol levels throughout the menstrual cycle, and the effect of estradiol on HDL cholesterol level was preserved in the follicular-phase subgroup analysis. It should be noted that the timing of two of three follicular-phase samples in this study was designed to occur near the midcycle estradiol surge. These findings are consistent with previous reports (3, 5, 7, 8) and, because we ablated endogenous estradiol production and provided replacement of natural estradiol via the more physiologic transdermal route (21) , this supports the premise that estradiol increases HDL cholesterol concentration.
The second objective of this study was to evaluate the acute effects of a commonly used monophasic combined hormonal OC on lipid metabolism (regression model 2). The effects of hormonal OCs are complex and due to many factors, including the type and dose of synthetic hormone provided in the OC. The OC used in our study provides a supraphysiologic dose of estrogen via ethinyl estradiol, contains the second-generation progestin levonorgestrel with androgenic properties, and results in inhibition of ovulation and luteal development (22) . The same OC formulation used in our study has previously been found to reduce HDL cholesterol level and increase LDL cholesterol and triglyceride levels in the circulation of premenopausal women after 6 to 12 months of administration (23) (24) (25) . In the current study, we obtained similar results for HDL cholesterol and triglyceride levels after one cycle of administration, with the OCs causing significantly increased triglyceride concentrations and a trend (P = 0.051) toward reduced HDL cholesterol levels relative to the normal menstrual cycle. We did not detect any effect of OCs on LDL cholesterol levels relative to the normal menstrual cycle. The HDL-level lowering effect of the OC is somewhat surprising given the supraphysiologic dose of estrogen in the OC (22) and the raising effect of natural estradiol on HDL cholesterol levels (21). However, progestins lower HDL cholesterol levels (21), which may override any beneficial effect from the estrogen. The increase in triglyceride concentration is consistent with the known effect of oral estrogens (21) . This study was designed to individually test the effects of estradiol and progesterone on the circulating lipid profile; the role of ovarian metabolism of lipids that occurs during the processes of follicular development, ovulation, as well as CL functions during the luteal phase; and the acute effects of a common monophasic combined hormonal OC on circulating lipids. One strength of our study is that we achieved an ethnically diverse study population, with half the participants identifying as white and half with minority racial backgrounds. Another strength is the crossover design, which increases statistical power. Finally, although numerous studies have evaluated the correlation among endogenous estradiol, progesterone, and circulating lipids during the menstrual cycle, in this study, we also inhibited endogenous production of these steroids and exogenously replaced them at physiologic concentrations to directly test steroid effects. Actual concentrations of estradiol and progesterone achieved during the artificial cycles were relatively similar to those detected in the natural cycle. The changes in lipid concentrations across this study appear to be modest (;4% to 10% in most comparisons). However, this is consistent with several reports that evaluated changes in lipid levels during the menstrual cycle (1) (2) (3) (4) (5) (6) (7) (8) , and small changes in lipid levels during a single menstrual cycle may have a substantial cumulative effect over a woman's reproductive lifespan.
There are limitations to the current study. Because of the amount of time (4 to 5 months) and number of clinic visits (up to 20) required of study participants, as well as adverse effects typical of simulated menopause, our sample size was relatively small, with 8 participants completing the entire study protocol and a ninth participant who completed the study through the OC cycle. Carryover effects are possible due to the necessity of administering interventions in the specified order to all participants. Estradiol and progesterone were replaced exogenously with bioidentical hormones, but an effect due to the route of administration cannot be ruled out. Furthermore, it is not possible, using exogenous hormone replacement, to exactly replicate the normal fluctuations and absolute concentrations of estradiol and progesterone that occur during the menstrual cycle.
Conclusion
We designed this study to evaluate the effect of ovarian lipid metabolism on serum lipid levels independent of the effects of ovarian-derived steroids. We compared lipid profiles during a natural cycle with patterns in the same women after simulated menopause induced by a GnRH agonist, and after hormone replacement with physiologic levels of natural estradiol and progesterone. Our results using this approach indicate that the CL consumes LDL to support steroidogenesis, which depletes circulating LDL during the luteal phase, and this is independent of estradiol and progesterone actions on the liver. Estradiol appears to be primarily responsible for increases in HDL cholesterol levels. The combination of high estradiol levels in the late follicular phase and high estradiol levels with luteal LDL cholesterol uptake during the luteal phase may collectively contribute to the favorable premenopausal lipid profile.
